A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-17 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Some hormonal birth control methods utilize cervical drug delivery methods. The earliest example of such dates to 1850 Ancient Egypt when acadia gum was inserted into the vagina, releasing spermicidal components. Examples in the modern era include vaginal rings and intrauterine devices (IUDs) that release hormones into the reproductive system to prevent fertilization. Vaginal rings are plastic ring-shaped devices that are inserted into the vaginal canal and slowly release hormones such as estradiol or progestin. Hormonal IUDs are T-shaped devices inserted into the uterus, releasing progestin over extended periods of time. These hormones work to thicken the cervical mucus to prevent sperm from penetrating and reaching the fallopian tubes. Copper IUDs are another form of intrauterine devices that release copper ions instead of hormones. The copper ions are toxic to sperm and therefore prevents successful fertilization.
A radio-frequency quadrupole (RFQ) beam cooler is a device for particle beam cooling, especially suited for ion beams. It lowers the temperature of a particle beam by reducing its energy dispersion and emittance, effectively increasing its brightness (brilliance). The prevalent mechanism for cooling in this case is buffer-gas cooling, whereby the beam loses energy from collisions with a light, neutral and inert gas (typically helium). The cooling must take place within a confining field in order to counteract the thermal diffusion that results from the ion-atom collisions. The quadrupole mass analyzer (a radio frequency quadrupole used as a mass filter) was invented by Wolfgang Paul in the late 1950s to early 60s at the University of Bonn, Germany. Paul shared the 1989 Nobel Prize in Physics for his work. Samples for mass analysis are ionized, for example by laser (matrix-assisted laser desorption/ionization) or discharge (electrospray or inductively coupled plasma) and the resulting beam is sent through the RFQ and "filtered" by scanning the operating parameters (chiefly the RF amplitude). This gives a mass spectrum, or fingerprint, of the sample. Residual gas analyzers use this principle as well.
Glucose uptake is the process by which glucose molecules are transported from the bloodstream into cells through specialized membrane proteins called glucose transporters, primarily via facilitated diffusion or active transport mechanisms: Facilitated Diffusion is a passive process that relies on carrier proteins to transport glucose down a concentration gradient. Secondary Active Transport is transport of a solute in the direction of increasing electrochemical potential via the facilitated diffusion of a second solute (usually an ion, in this case Na+) in the direction of decreasing electrochemical potential. This gradient is established via primary active transport of Na+ ions (a process which requires ATP).
RdRps can be used as drug targets for viral pathogens as their function is not necessary for eukaryotic survival. By inhibiting RdRp function, new RNAs cannot be replicated from an RNA template strand, however, DNA-dependent RNA polymerase remains functional. Some antiviral drugs against Hepatitis C and COVID-19 specifically target RdRp. These include Sofosbuvir and Ribavirin against Hepatitis C and remdesivir, an FDA approved drug against COVID-19 GS-441524 triphosphate is a substrate for RdRp, but not mammalian polymerases. It results in premature chain termination and inhibition of viral replication. GS-441524 triphosphate is the biologically active form of remdesivir. Remdesivir is classified as a nucleotide analog that inhibits RdRp function by covalently binding to and interrupting termination of the nascent RNA through early or delayed termination or preventing further elongation of the RNA polynucleotide. This early termination leads to nonfunctional RNA that gets degraded through normal cellular processes. Baloxavir marboxil is an approved drug for the treatment of influenza infection. In addition, suraxavir marboxil and tivoxavir marboxil are currently undergoing clinical trials for the same indication. The development of an other inhibitor pimodivir, has been halted.
Sources: en.wikipedia.org
However, a June 2017 study found that (2R,6R)-HNK does in fact block the NMDA receptor, similarly to ketamine. These findings suggest that the antidepressant-like effects of (2R,6R)-HNK may not actually be NMDA receptor-independent and that it may act in a similar manner to ketamine. Ketamine, (2R,6R)-HNK, and (2S,6S)-HNK have been found to be possible ligands of the estrogen receptor ERα (IC50 = 2.31, 3.40, and 3.53 μM, respectively). In 2024, HNK was found to act as a highly potent positive allosteric modulator of the opioid receptors, including of the μ-opioid receptor (MOR). It shares this action with ketamine and norketamine. They are all active in this action at very low concentrations, for instance 1 nM. Ketamine, norketamine, and HNK can potentiate the effects of endogenous opioids like met-enkephalin and exogenous opioids like morphine. Opioid receptor positive allosteric modulation by these agents may be involved in their therapeutic effects, for instance their antidepressant and analgesic effects.
== Description == The shroud is rectangular, measuring approximately 4.4 by 1.1 metres (14 ft 5 in × 3 ft 7 in). The cloth is woven in a three-to-one herringbone twill composed of flax fibrils. Its most distinctive characteristic is the faint, brownish image of a front and back view of a naked man with his hands folded across his groin. The two views are aligned along the midplane of the body and point in opposite directions. The front and back views of the head nearly meet at the middle of the cloth. The image in faint straw-yellow colour on the crown of the cloth fibres appears to be of a man with a beard, moustache, and shoulder-length hair parted in the middle. He is muscular and tall (various experts have measured him as from 1.70 to 1.88 m or 5 ft 7 in to 6 ft 2 in). Reddish-brown stains are found on the cloth, correlating with the wounds in the Biblical description of the crucifixion of Jesus. The shroud was damaged in a fire in 1532 in the chapel in Chambéry, France. There are some burn holes and scorched areas down both sides of the linen, caused by contact with molten silver during the fire that burned through it in places while it was folded. Fourteen large triangular patches and eight smaller ones were sewn onto the cloth by Poor Clare nuns to repair the damage. In May 1898 the Italian photographer Secondo Pia was allowed to photograph the shroud. He took the first photograph of the shroud on 28 May 1898. In 1931, another photographer, Giuseppe Enrie, photographed the shroud and obtained results similar to Pia's.
=== Quantitative analysis of mixtures === FD-MS can also be used for quantitative analysis when the method of internal standard is applied. There are two common modes of adding an internal standard: either addition of a homologous compound of known weight to the sample, or addition of an isotopically substituted compound of known weight to it. Many earlier applications of FD to analysis of polar and nonvolatile analytes such as polymers and biological molecules have largely been supplanted by newer ionization techniques. However, FD remains one of the only ionization techniques that can produce simple mass spectra with molecular information from hydrocarbons and other particular analytes. The most commonly encountered application of FD at the present time is the analysis of complex mixtures of hydrocarbons such as that found in petroleum fractions.
Sources: en.wikipedia.org
=== The Pékerman era and the golden generation (2011–2018) === At the 2011 Copa América in Argentina, Colombia won Group A ahead of the hosts with seven points and without conceding, beating Costa Rica 1–0 and Bolivia 2–0 either side of a goalless draw with Argentina, but were eliminated 2–0 by Peru in the quarter-finals at Córdoba after extra time. José Pékerman, the Argentine who had taken his own country to the 2006 World Cup quarter-finals, was appointed head coach in January 2012. Colombia finished second in the CONMEBOL qualifiers with 30 points to reach the 2014 FIFA World Cup, ending a sixteen-year absence, and conceded only 13 goals — the second-best defensive record in the group behind Argentina.
The pelycosaurs are synapsids (more closely related to mammals) while the ctenosauriscids are archosaurs (closely related to crocodilians, pterosaurs and dinosaurs). Also, the spinosaurids had sail-like fins on their backs, when they were not closely related to either. Also, Acrocanthosaurus and Ouranosaurus, which are not closely related to either pelycosaurs, ctenosauriscids or spinosaurids, also had similar, but thicker, spines on their vertebrae. Noasaurus, Baryonyx, and Megaraptor, all unrelated, all had an enlarged hand claw that were originally thought to be placed on the foot, as in dromaeosaurs. A similarly modified claw (or in this case, finger) is on the hand of Iguanodon. The ornithopods had feet and beaks that resembled that of birds, but are only distantly related. Three groups of dinosaurs, the Tyrannosauridae, Ornithomimosauria, and the Troodontidae, all evolved an arctometatarsus, independently. Some placodonts (like Cyamodus, Psephoderma, Henodus and especially Placochelys) bear striking resemblance to sea turtles (and turtles in general) in terms of size, shell, beak, mostly toothless jaws, paddle-shaped limbs and possibly other adaptations for aquatic lifestyle.
Librarian Ainsworth Rand Spofford, who directed the Library of Congress from 1865 to 1897, built broad bipartisan support to develop it as a national library and a legislative resource. He was aided by expansion of the federal government after the war and a favorable political climate. He began comprehensively collecting Americana and American literature, led the construction of a new building to house the library, and transformed the librarian of Congress position into one of strength and independence. Between 1865 and 1870, Congress appropriated funds for the construction of the Thomas Jefferson Building, placed all copyright registration and deposit activities under the library's control, and restored the international book exchange. The library also acquired the vast libraries of the Smithsonian and of historian Peter Force, strengthening its scientific and Americana collections significantly. By 1876, the Library of Congress had 300,000 volumes; it was tied with the Boston Public Library as the nation's largest library. It moved from the Capitol building to its new headquarters in 1897 with more than 840,000 volumes, 40 percent of which had been acquired through copyright deposit. A year before the library's relocation, the Joint Library Committee held hearings to assess the condition of the library and plan for its future growth and possible reorganization. Spofford and six experts sent by the American Library Association testified that the library should continue its expansion to become a true national library.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.